264 related articles for article (PubMed ID: 17482893)
41. Enhanced in vivo selection of bone marrow cells by retroviral-mediated coexpression of mutant O6-methylguanine-DNA-methyltransferase and HOXB4.
Milsom MD; Woolford LB; Margison GP; Humphries RK; Fairbairn LJ
Mol Ther; 2004 Nov; 10(5):862-73. PubMed ID: 15509504
[TBL] [Abstract][Full Text] [Related]
42. Human variants of O6-alkylguanine-DNA alkyltransferase.
Pegg AE; Fang Q; Loktionova NA
DNA Repair (Amst); 2007 Aug; 6(8):1071-8. PubMed ID: 17482892
[TBL] [Abstract][Full Text] [Related]
43. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model.
Neff T; Horn PA; Peterson LJ; Thomasson BM; Thompson J; Williams DA; Schmidt M; Georges GE; von Kalle C; Kiem HP
J Clin Invest; 2003 Nov; 112(10):1581-8. PubMed ID: 14617759
[TBL] [Abstract][Full Text] [Related]
44. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
Persons DA; Allay ER; Sawai N; Hargrove PW; Brent TP; Hanawa H; Nienhuis AW; Sorrentino BP
Blood; 2003 Jul; 102(2):506-13. PubMed ID: 12663444
[TBL] [Abstract][Full Text] [Related]
45. In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy.
Chen Y; Schroeder JA; Gao C; Li J; Hu J; Shi Q
J Cell Physiol; 2021 Jan; 236(1):354-365. PubMed ID: 32510630
[TBL] [Abstract][Full Text] [Related]
46. Transfer of drug resistance genes in hematopoietic progenitors for chemoprotection: is it still an option?
Laufs S; Buss EC; Zeller WJ; Fruehauf S
Drug Resist Updat; 2003 Apr; 6(2):57-69. PubMed ID: 12729804
[TBL] [Abstract][Full Text] [Related]
47. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ
J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413
[TBL] [Abstract][Full Text] [Related]
48. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
Xin L; Tan Y; Zhu Y; Cui X; Wang Q; Zhao J; Tian S; Xu C; Xiao M; Hong B; Xu J; Yuan X; Wang C; Kang C; Fang C
Neuro Oncol; 2023 Nov; 25(11):1976-1988. PubMed ID: 37279651
[TBL] [Abstract][Full Text] [Related]
49. A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines.
Richard E; Géronimi F; Lalanne M; Ged C; Redonnet-Vernhet I; Lamrissi-Garcia I; Gerson SL; de Verneuil H; Moreau-Gaudry F
J Gene Med; 2003 Sep; 5(9):737-47. PubMed ID: 12950064
[TBL] [Abstract][Full Text] [Related]
50. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
[TBL] [Abstract][Full Text] [Related]
51. Gene therapy with drug resistance genes.
Zaboikin M; Srinivasakumar N; Schuening F
Cancer Gene Ther; 2006 Apr; 13(4):335-45. PubMed ID: 16211086
[TBL] [Abstract][Full Text] [Related]
52. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication.
Davis BM; Humeau L; Dropulic B
Mol Ther; 2004 Feb; 9(2):160-72. PubMed ID: 14759800
[TBL] [Abstract][Full Text] [Related]
53. Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents.
Wang G; Weiss C; Sheng P; Bresnick E
Biochem Pharmacol; 1996 May; 51(9):1221-8. PubMed ID: 8645346
[TBL] [Abstract][Full Text] [Related]
54. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
55. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
56. In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.
Schroeder JA; Chen Y; Fang J; Wilcox DA; Shi Q
J Thromb Haemost; 2014 Aug; 12(8):1283-93. PubMed ID: 24931217
[TBL] [Abstract][Full Text] [Related]
57. Efficient protection of cells from the genotoxicity of nitrosoureas by the retrovirus-mediated transfer of human O6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1.
Suzuki M; Sugimoto Y; Tsuruo T
Mutat Res; 1998 Jun; 401(1-2):133-41. PubMed ID: 9639692
[TBL] [Abstract][Full Text] [Related]
58. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy.
Adair JE; Beard BC; Trobridge GD; Neff T; Rockhill JK; Silbergeld DL; Mrugala MM; Kiem HP
Sci Transl Med; 2012 May; 4(133):133ra57. PubMed ID: 22572881
[TBL] [Abstract][Full Text] [Related]
59. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Wu Q; Berglund AE; Macaulay RJ; Etame AB
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
[TBL] [Abstract][Full Text] [Related]
60. Glioblastoma Recurrence and the Role of O
Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
